Riskpilot← Back to searchSign inGet full accessLABO ROSE UTVIKLING AS
ASActiveOrg 917743185Prinsegata 4, 3256 LarvikUtleie av egen eller leid fast eiendom ellers · NACE 68209Est. 20160 employees
Revenue 2023
NOK 0
EBITDA margin
—
-25% vs 2022
Equity ratio
-226.4%
Financial strength
Net profit 2023
NOK -267K
-25% vs 2022
| Revenue | NOK 0 | — |
| EBITDA | NOK -267K | -25% |
| Net profit | NOK -267K | -25% |
| Total assets | NOK 45K | -77% |
| Equity | NOK -101K | -161% |
| Employees | 0 | — |
Legal name
LABO ROSE UTVIKLING AS
Org number
917743185
Legal form
Aksjeselskap
NACE code
68209 · Utleie av egen eller leid fast eiendom ellers
Founded
19. september 2016
Share capital
NOK 60 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Selskapets formål er kjøp, eie, inn- og utleie og salg av eiendommer og eiendomsandeler og alt som står i forbindelse dermed, herunder deltagelse i andre selskaper.
Address
Prinsegata 4, 3256 Larvik
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 95 | 225 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −176 | 81 | −230 | −213 | −267 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −176 | 81 | −230 | −213 | −267 |
| Net financials | 23 | 13 | 0 | 0 | 0 |
| Profit before tax | −154 | 94 | −230 | −213 | −267 |
| Tax | 0 | −0 | −0 | −0 | −0 |
| Net profit | −154 | 94 | −230 | −213 | −267 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 3 148 | 1 334 | 468 | 191 | 45 |
| Equity | 1 115 | 609 | 379 | 166 | −101 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 034 | 725 | 89 | 24 | 145 |
| Total debt | 2 034 | 725 | 89 | 24 | 145 |
EBITDA margin
-26714400.0%
This company
15.8%
Market median
-169078581% vs market
20192023
Equity ratio
-226.4%
This company
38.2%
Market median
-693% vs market
20192023
Return on equity
-26714400.0%
This company
18.4%
Market median
-145187057% vs market
20192023
Net profit margin
-26714400.0%
This company
8.1%
Market median
-329807507% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
1.44×
This company
0.62×
Market median
-132% vs market
20192023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2016 | |
| Board of Directors | 2016 | |
| Board of Directors | 2016 | |
| Board of Directors | 2016 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2024 | |
| Company | 50% | 50% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oppigard V Hmc As
LABO ROSE UTVIKLING AS Board members of LABO ROSE UTVIKLING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Asle Frantsvåg Granerud | Chairman | 0 companies |
| Ståle Idar Langfeldt Boye | Board of Directors | 0 companies |
| Øyvind Berge | Board of Directors | 0 companies |
| Gunnar Svarstad | Board of Directors | 0 companies |